Targeting TAM to Tame Pancreatic Cancer
File version
Author(s)
Burke, Michael C
Brekken, Rolf A
Aguilera, Todd A
Zeh, Herbert J
Beg, Muhammad Shaalan
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Pancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mechanistic investigations and therapeutic combinations in the preclinical setting suggest that TAM inhibition with chemotherapy, targeted therapy, and immunotherapy should be evaluated clinically.
Journal Title
Targeted Oncology
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
This publication has been entered in Griffith Research Online as an advanced online version.
Access the data
Related item(s)
Subject
Oncology and carcinogenesis
Science & Technology
Life Sciences & Biomedicine
RECEPTOR TYROSINE KINASE
EPITHELIAL-MESENCHYMAL TRANSITION
Persistent link to this record
Citation
von Itzstein, MS; Burke, MC; Brekken, RA; Aguilera, TA; Zeh, HJ; Beg, MS, Targeting TAM to Tame Pancreatic Cancer, Targeted Oncology, 2020